Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults EP News Bureau Aug 31, 2020 Results from the Phase III EMPEROR-Reduced trial were published in The New England Journal of Medicine
DRL in collaboration with Amgen in India Sanjiv Das Aug 6, 2015 DRL to market and distribute Amgen’s Repatha, Kyprolis and BLINCYTO in India upon approval Dr Reddy’s Laboratories (DRL) has…
